Glucose status in patients with acromegaly receiving primary treatment with the somatostatin analog lanreotide.
about
Clinical applications of somatostatin analogs for growth hormone-secreting pituitary adenomasLanreotide autogel(®): a review of its use in the treatment of patients with acromegaly.Adverse events associated with somatostatin analogs in acromegaly.Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly.Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management.Marked alteration of glycemic profile surrounding lanreotide administration in acromegaly: A case report.
P2860
Glucose status in patients with acromegaly receiving primary treatment with the somatostatin analog lanreotide.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Glucose status in patients wit ...... omatostatin analog lanreotide.
@en
Glucose status in patients wit ...... omatostatin analog lanreotide.
@nl
type
label
Glucose status in patients wit ...... omatostatin analog lanreotide.
@en
Glucose status in patients wit ...... omatostatin analog lanreotide.
@nl
prefLabel
Glucose status in patients wit ...... omatostatin analog lanreotide.
@en
Glucose status in patients wit ...... omatostatin analog lanreotide.
@nl
P2093
P2860
P1433
P1476
Glucose status in patients wit ...... omatostatin analog lanreotide.
@en
P2093
Antoine Bennet
Elisabeth Couture
Jean-Christophe Maiza
Philippe Caron
P2860
P2888
P304
P356
10.1007/S11102-011-0361-9
P577
2012-12-01T00:00:00Z